Key facts
- Health minister James Frith told MPs the government plans to end Palantir's NHS data platform contract in 2029.
- Formal procurement for a new contract will begin in the second half of 2027 and is expected to take 18 months.
- Frith described the extension of Palantir's contract until 2029 as "a bridge, not the destination."
- Two parliamentary committees have called for Palantir's NHS contract to be ended in the last year.
- A Palantir spokesperson said the announcement was "good news for patients and for the NHS."
The UK government confirmed it plans to end Palantir Technologies' contract to provide a data platform for the National Health Service in 2029, health minister James Frith told MPs on November 16, 2026. The government will not sever the contract immediately, as some MPs and campaigners had pushed it to do.
Formal procurement for a new contract will begin in the second half of 2027 and is expected to take 18 months, Frith said. He described the extension of Palantir's contract until 2029 as "a bridge, not the destination."
Frith said the new procurement round will bake in "interoperability, resilience and trusted common standards" in a bid to regain "public trust" and open up opportunities for "U.K. sovereign capabilities." Non-UK firms will also be encouraged to bid, he said.
"We want to give the health and care system more choice, greater resilience and less dependence on any single supplier, as well as the ability to adapt and evolve as new technologies emerge in future, with better value for taxpayers through time," Frith said. He added that the approach will stimulate a more diverse supplier market, including greater use of sovereign AI and internationally developed capabilities.
Palantir's contract has drawn scrutiny from campaigners, health professionals and MPs over controversial views expressed by the company's founders and concerns about vendor lock-in. Two parliamentary committees have called for the contract to be ended in the last year.
A Palantir spokesperson said the announcement was "good news for patients and for the NHS" and that the company was "proud" of its work. "We will now redouble our efforts over the next two years to continue and accelerate that support," as well as "deepen our investment in the U.K.," the spokesperson said.
